Diabetes mellitus (DM) is an important risk factor for atherothrombosis. 1 Despite advances in the treatment of both DM and cardiovascular disease, patients with DM are not only at increased risk for cardiovascular events, but also have greater morbidity and mortality when such events occur. 2, 3 As the global population becomes more sedentary and obesity becomes more common, the prevalence of DM is increasing and is likely to continue to do so. As a result, the attributable risk for atherothrombotic events associated with DM is increasing. 4 The association between DM and atherothrombosis is likely multifactorial. 4 At least in part, enhanced platelet reactivity is believed to predispose patients with DM to thrombosis. 5, 6 Antithrombotic therapies, such as glycoprotein IIb/IIIa antagonists, enoxaparin, and prasugrel, have shown a consistent pattern of greater absolute and, in some cases, greater relative benefit in patients with DM compared with patients without this condition. [7] [8] [9] [10] Vorapaxar is a first-in-class protease activated receptor (PAR)-1 antagonist that potently inhibits thrombin-induced activation of platelets. Vorapaxar is effective for secondary prevention in patients with a history of atherosclerosis while increasing moderate or severe bleeding. 10, 11 Because of this tradeoff in potential benefit versus risk, it is of interest to identify patients, in particular among those with a history of myocardial infarction (MI), who may be appropriate candidates for treatment with vorapaxar. 11 Therefore, in the present analysis, we examined the efficacy and safety of vorapaxar for secondary prevention of cardiovascular (CV) events in patients with and without DM who were enrolled in a large, randomized trial of vorapaxar vs. placebo in the 2 weeks to 1 year after a qualifying MI.
Methods

Study Population
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The Institutional Review Board or Ethics Committee for each participating institution trial reviewed and approved the trial. All patients gave written informed consent.
Endpoints
The primary endpoint for this analysis was the composite of CV death, MI, or stroke. 13 The key secondary endpoint was the composite of the primary endpoint or recurrent ischemia leading to urgent revascularization. Bleeding was classified using the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) definition. 14 A blinded clinical events committee adjudicated all elements of the primary and secondary efficacy endpoints as well as all bleeding events in the trial.
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Statistical Methods
A pre-specified analysis was performed based on the patient's history of DM as recorded by the local investigator at the time of randomization. Comparisons of baseline characteristics between patients with and without DM were made using the 2 test for categorical variables and the Wilcoxon rank-sum test for continuous variables. A Cox proportional-hazard model was used for the efficacy analyses with the investigational treatment allocation and planned use of a thienopyridine as covariates. The interaction of diabetes with the randomized treatment was assessed in the overall US approval cohort with the addition of an interaction term (diabetes x treatment allocation) to the Cox proportional hazard model along with each of the main effects.
Interaction p-values <0.10 were considered evidence of a possible interaction. Kaplan-Meier 3-year cumulative event rates are presented with patients censored at the occurrence of an endpoint or at the time of the last visit. Analyses of bleeding were performed in patients who received 1 or more doses of study drug. These analyses included all events that occurred from the first dose of study drug until 30 days after a final visit at the conclusion of the trial or 60 days after premature drug discontinuation.
13
A Cox proportional hazard survival model was developed in order to describe the association between diabetes and the risk of CV death, MI, or stroke. Given the differences in patients with and without diabetes, the model included covariates which were thought to be potential confounders a priori (treatment allocation, age, sex, race, history of hypertension, history of hyperlipidemia, ongoing tobacco abuse, history of peripheral arterial disease, history of stroke or TIA, history of congestive heart failure, creatinine clearance < 60 ml/min, weight <60 kg and region). The proportional hazard assumption was tested using visual inspection of the Schoenfeld residuals.
Analyses were performed with Stata version 12.1 (StataCorp LP, College Station, TX).
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Results
Among the 16,896 patients with a prior MI and no prior stroke or TIA randomized, 3,623 (21%) had DM. Patients with DM were older, more often female, and were more likely to have hypertension, peripheral arterial disease, renal dysfunction, and obesity ( Table 1) . The majority (84%) of the patients with DM were being treated with either insulin or non-insulin therapies for hyperglycemia. Evidenced based therapies for secondary prevention of atherothrombosis were used in a high proportion of both patients with and without DM ( Table 1 ). The baseline characteristics in patients with and without diabetes stratified by treatment allocation were similar (Supplemental Table 3 ).
Cardiovascular Outcomes and Bleeding in Diabetes
Among placebo-allocated patients, those with DM, when compared to those without, had nearly double the incidence of CV death, MI, or stroke at 3 years (14.3% vs. 7.6%, p<0.001). After adjusting for potential confounders (treatment allocation, age, sex, race, history of hypertension, history of hyperlipidemia, ongoing tobacco abuse, history of peripheral arterial disease, history of stroke or TIA, history of congestive heart failure, creatinine clearance < 60 ml/min, weight <60 kg and region), DM was still associated with a 47% higher risk of CV death, MI, or stroke (HR adj 1.47, 95% CI 1.24-1.75; p<0.001; Figure 1 ). Patients with DM were also at increased risk of the individual endpoints of CV death (4.4% vs. 1.7%, HR adj 1.58, 95% CI 1.13-2.21; p=0.008) and recurrent MI (10.2% vs. 5.6%, HR adj 1.46, 95% CI 1.20-1.79; p<0.001), with a trend toward a higher risk of stroke (2.5% vs. 1.1%, HR adj 1.54, 95% CI 1.00-2.37; p=0.051). The risk of GUSTO moderate/severe bleeding was similar in patients with and without diabetes (2.6% vs.
1.9%, HR adj 0.93, 95% CI 0.63-1.38; p=0.72).
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Efficacy and Safety of Vorapaxar
In This pattern of a consistent relative risk reduction and greater absolute benefit in patients with DM was apparent across all components of the primary endpoint ( Table 2 ). The relative effect of vorapaxar on ischemic endpoints was nominally greater in patients with than without DM, including recurrent ischemia leading to urgent revascularization (p-interaction=0.02) and coronary revascularization with either PCI or CABG (p-interaction=0.008, Figure 3 ).
An increase in moderate or severe bleeding with vorapaxar in patients with DM (4.4% vs.
2.6%; HR 1.60, 95% CI 1.07-2.40) was similar to that for patients without DM (pinteraction=0.93, Table 3 ). Two pre-specified composite endpoints of net clinical outcome were evaluated ( This p pat att te er rn n o of f f a a co co ons ns nsis is ste tent nt nt r r rel elat ati i ive r r ris sk re e ed du ucti io ion n a an nd d d gr grea a ate ter a ab a s so solu lu ute te e b ben en nef ef efit it i i in p pa pati ti t en en nts wi wi ith th th D D DM M wa wa was s ap ap ppa pa are ren nt nt a a acr cros ss s s al al all l l co co comp mp pon on nen en ents ts o o of f t th the e e pr pr rim m mar ar ary y en en end dp dpoi oi oint nt n (T Ta Tabl bl ble e 2 2 2). ). ) Th T The e re e ela lati tiv ve ve effect of vora rapa pa paxa xa ar r r on on on i isc s s he he hemi m m c c c en en endp dp dpoi i int nt n s s s wa wa was s s no no nomi mi mina n n ll ll ly y y gr gr grea ea eate te ter r r in n n p p pat at atie ie ient nt nts s s wi wi w th th th t tha ha han n n without n n n moderate/severe bleeding (HR 0.79, 95% CI 0.67-0.93, p=0.005) as well as the composite of death, MI, stroke, or GUSTO severe bleeding (HR 0.77; 95% CI 0.65-0.93). Notably, the absolute risk difference for CV Death, MI, Stroke, RIUR, or GUSTO moderate/severe bleed in patients with DM was -3.89% (95% CI -1.34, -6.11) and in those without DM was -0.53% (95% CI 0.61, -1.57).
Discussion
Vorapaxar is a novel platelet inhibitor that is effective for the secondary prevention of atherothrombosis. As with other potent antiplatelet agents, its clinical use should take into account an individualized assessment of the potential antithrombotic benefits and risk of bleeding. Our findings from the TRA2°P-TIMI 50 trial showed a higher risk of recurrent major CV events in diabetic than in non-diabetic patients with established atherosclerosis despite standard medical therapy. When added to these standard therapies, treatment with vorapaxar reduced CV death, MI, or stroke in this high risk group. Owing to their higher cumulative risk, patients with DM had a potential greater absolute risk reduction than patients without DM which translates into fewer patients needed to treat in order to prevent a major CV event (Figure 2 ).
Diabetes Mellitus and Secondary Prevention
Patients with established atherosclerosis who have DM have a high residual risk of recurrent events despite treatment with intensive medical therapy. [15] [16] [17] [18] This increased risk is related to the high prevalence of other risk factors in patients with DM (e.g. hypertension and obesity), as well as the direct adverse pathological consequences of DM, including endothelial dysfunction, vascular inflammation, abnormal platelet reactivity, and decreased responsiveness to commonly used therapies. 19 Notably, we found that after adjusting for potential confounders, despite use of account an individualized assessment of the potential antithrombotic benefits and nd d ris is i k k k of of of bleeding. Our findings from the TRA2°P-TIMI 50 trial showed a higher risk of recurrent major CV CV V e e eve ve ve t nt nts s s in in in dia a abe be beti t c than in non-diabetic patien n nt ts t w with establishe he ed at the he her ro rosclerosis despite t tan n nda d rd medic ical al a t the hera ra apy py y. W W Whe h hen n ad ad adde ded d t to th he hese s st ta an nda a ard rd d t th he her ra rap pi ies s, tr tre eat tm men en nt t t wi with th th v v vor orap ap pa ax axa a ar e edu du duce ce ced d d CV CV V d d dea eat th th, , MI MI I, o or or str r rok ok oke e e in in in t thi his s s hi hi high gh gh ri ri isk sk s g gr ro roup up up. Ow Ow Owin n ng g g t to to t t the he h ir ir r h h hig igh he her r r cu cumu mu mula at t tiv ve ve r ri is isk, k, k, patients with h DM DM DM h h had ad a a a p pot ot oten en ential al al gr gr grea ea e te te er r r ab ab abso so solu lu lute te e r r ris is sk k re re edu du duct ct ctio io on n n th t t an an an p p pat at atie ie ient nt n s s wi wi with th thou ou out t DM which h h aspirin in 98%, lipid-lowering agents in 97%, and renin-angiotensin pathway antagonists in 78%, patients with DM were still at 47% increased risk of major CV events. As the prevalence of DM increases, the secondary prevention of atherothrombosis will assume heightened importance in this high-risk group.
Vorapaxar and Secondary Prevention
In light of the increased reactivity of platelets that contributes to the adverse CV outcomes in patients with DM, 6 this group of patients was identified at the initiation of TRA 2°P-TIMI 50 as a population of particular interest. 6, 18, 20 We have shown previously that potent inhibition of the platelet P2Y 12 receptor pathway with prasugrel in patients presenting with an acute coronary syndrome offers a greater benefit in patients with DM compared with non-diabetics. 9 Similarly, patients with HbA1c 6% had evidence of a greater benefit from treatment with ticagrelor. 18 Our data raise the possibility that vorapaxar, which inhibits platelets via a pathway separate from that of aspirin and P2Y12 inhibitors, similarly offers a particular advantage for patients with DM.
First, we found that there was a consistent reduction in major CV events with vorapaxar added to standard therapy among patients with DM. Second, because of their higher rate of recurrent CV events, patients with DM had a higher absolute risk reduction and a NNT of 29 compared to 74 in patients without diabetes. Third, a nominal treatment interaction was observed such that compared with patients without DM, patients with DM had a significantly greater relative reduction in hospitalization for unstable angina or coronary revascularizations.
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Fi Firs rs st, t, t, w we e fo o oun und d d t th hat at t the he h re re re w w wa as as a a a c c con on ons s sist st ten en e t t t re re edu u uct ct tio io ion n n in in n m m maj aj jor or or C C CV V V ev ev ven en ents ts t w w wit it ith h v v vor ra rapa pa axa a ar r coronary syndrome). 7 In light of these findings, when weighing the risk of bleeding with the antithrombotic benefits of vorapaxar, patients with DM appear to be particularly appropriate candidates for consideration for treatment with this new therapy.
Limitations
These findings should be considered in the context of the limitations of the study. First, our observations are based upon subgroups in the overall trial. However, this analysis was prespecified and the subgroups were large. Patients with diabetes can differ in the duration of the disease, degree of glycemic control and presence of other medical comorbidities. Given the randomized nature of the study, these characteristics were likely balanced between the vorapaxar and placebo groups and thus not expected to influence the treatment comparison. However, it is possible that the magnitude of our observed effect may not apply to the entire spectrum of manifestations of diabetes. Second, the nominally significant interaction in the efficacy of vorapaxar with regard to ischemic endpoints should be regarded as hypothesis generating. Third, because the data were not captured in this trial, we are unable to perform additional exploratory analyses based on glycemic control or length of time in which patients have had DM.
Conclusions
Vorapaxar is an additional treatment option for long-term secondary prevention in patients with DM who have had a prior MI, in the absence of a prior stroke or TIA. DM is a high risk indicator that identifies patients who appear to have a particularly favorable balance of antithrombotic efficacy and bleeding with vorapaxar.
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